- 1 Evaluation of serological tests for detecting SARS-CoV-2 antibodies: implementation in
- 2 assessing post vaccination status
- 3 Running title: Evaluation of serological tests for detecting SARS-CoV-2 antibodies
- 4 Authors' details
- 5 1.Dr. Sally A. Mahmoud (Corresponding author)
- 6 Biogenix Lab G42, Abu Dhabi, UAE
- 7 Email ID: sally.abdulla@g42.ai
- 8 2.Dr. Subhashini Ganesan
- 9 G42 Healthcare, UAE
- 10 Email ID: Subhashini.g@g42.ai
- 11 3.Mr. Shivaraj Naik
- 12 Biogenix Lab G42, Abu Dhabi, UAE
- Email ID: shivaraj.Naik@g42.ai
- 14 4 Ms. Safaa Bissar
- 15 Biogenix Lab G42, Abu Dhabi, UAE
- 16 Email ID: <u>Safaa.Bissar@g42.ai</u>
- 5.Ms. Isra Zamil
- 18 Biogenix Lab G42, Abu Dhabi, UAE
- 19 Email ID: <u>Isra.Zamil@g42.ai</u>
- 20 6.Dr.Walid Abbas Zaher
- 21 G42 Healthcare, UAE
- 22 Email ID: Walid.Zaher@g42.ai

Abstract

25

26

28

29

30

31

Background

27 The anti-SARS-CoV-2 immunological assays have promising applications in the control and

surveillance of the current COVID-19 pandemic. Therefore, large number of serological

assays are developed in the commercial market to measure SARS-CoV-2 antibodies, which

requires evaluation before their application in large scale.

Objectives

- 32 To evaluate the performances of commercially available serological assays for detecting
- 33 SARS-CoV-2 antibodies.

34 **Methods**

- 35 The study compared the performances of six different methods for detection of antibodies
- 36 against SARS-CoV-2 which includes (i) Genscript SARS-CoV-2 surrogate virus
- 37 neutralization test kit [Test A] (ii) Diasorin SARS-CoV-2 S1/S2 IgG detection [Test B] (iii)
- 38 Alinity SARS-CoV-2 IgG II [Test C] (iv) Diasorin SARS-CoV-2 TrimericS IgG [Test D]
- 39 (v) Roche Elecsys Anti-SARS-CoV-2 cobas [Test E] (vi) AESKULISA (AESKU Enzyme
- 40 Linked Immunosorbent Assay) [Test F] against the gold standard Plaque Reduction
- 41 Neutralization Test (PRNT).

42 Results

- Test E had the highest sensitivity and Test A had the highest specificity The ROC for tests A,
- C, D and E showed optimum cut-offs that differed from the manufacturer's recommendation.
- 45 Test D had the best performance considering all the performance indicators with the highest
- 46 agreement with the PRNT results. Parallel testing of test A with test D and test B had the
- 47 optimum performance.

Conclusion

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

Serological assays that are commercially available are very promising and show good

agreement with the standard PRNT results. Studies on large samples for optimization of the

assay cut-off values and cost-effective evaluations on parallel testing methods are needed to

make recommendations on these commercial assays.

Importance

Serological assays that are commercially available are very promising and this paper adds

new knowledge about the optimization of these kits for evaluating post vaccination antibodies

status. It highlights the positive and negative aspects of each of these assays in terms of

sensitivity, specificity, positive and negative predictive values, and the agreement of results

with the standard neutralization test. When serological assays are being used to assess post-

vaccine immune status, a balance of all parameters needs to be considered rather than

emphasizing only on high specificity. This is particularly relevant in the current situation

where vaccination is happening around the globe, high sensitivity assays will result in

reporting a lower percentage of false negative reports and avoids panic about lack of vaccine

response. It is important that we understand the strengths and limitations of commercially

available serological assays for better application of these tests to understand immune

response and the duration of protection post vaccination.

Key words: SARS-CoV-2; Serological assays; COVID-19; ELISA; CLIA

Background

The emergence of this global pandemic of COVID-19 has created an increased need for large

scale PCR testing and serological assays. Serological testing has enormous applications in

handling the current pandemic, it has both individual and population level practical

applications that can facilitate pandemic response. At the individual level it can help

G42-Public

differentiate recent and past infections of COVID-19, immune status post-vaccination to study the need for booster doses and identifying vaccine intervals. At the population level it helps study the epidemiology of SARS-CoV-2 pandemic, seroprevalence, and thereby help public health experts make recommendations on travel, social distancing, and the protective status of the population. [1] There are several serodiagnosis assay platforms that are being used for COVID-19 infections: the FDA has issued emergency authorization for ELISA, lateral flow immunoassay, and microsphere immunoassay. [2] These tests measure the antibody to nucleocapsid N protein antigens and antibodies binding to SARS-CoV-2 spike protein S, but not all spike-binding antibodies are functional or blocks viral infection, hence they do not indicate the functional measure of the antibody that inhibits SARS-CoV-2 infection. Ideally, tests should measure the neutralizing antibodies, which implicate protection from infection. The gold standard for measuring neutralizing antibodies is the plaque reduction neutralization test (PRNT). PRNT is however not practical for large scale as it requires skilled manpower, high-level biohazard security (BSL-3 level) and requires long turnaround time of five days. [3,4] Therefore, to address this gap, a lot of commercial serological assays are developed and are now available in the market. A meta-analysis done on these serological assays for detecting antibodies against SARS-CoV-2 have shown that assays using the S antigen and testing IgG antibodies perform with better sensitivity than N antigen and Ig M based tests. [5] It is important that we understand the strengths and limitations of commercially available serological assays for better application for these tests to understand immune response and the protection and duration of protection after vaccination. Hence this research tries to evaluate the various methods for detecting SARS-CoV-2 antibodies compared to the gold standard PRNT.

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

Objective

96 97 To evaluate the performances of commercially available serological assays for detecting 98 SARS-CoV-2 antibodies 99 Methods 100 The study compared six different methods for detection of antibodies against SARS-CoV-2 101 detection post vaccination for COVID-19 against the gold standard Plaque Reduction 102 Neutralization Test (PRNT). The six different methods are (i) Genscript SARS-CoV-2 surrogate virus neutralization test kit [Test A] (ii) Diasorin - SARS-CoV-2 S1/S2 IgG 103 104 detection [Test B] (iii) Alinity SARS-CoV-2 IgG II [Test C] (iv) Diasorin - SARS-CoV-2 105 TrimericS IgG [Test D] (v) Roche Elecsys Anti-SARS-CoV-2 – cobas [Test E] (vi) 106 AESKULISA (AESKU Enzyme Linked Immunosorbent Assay) [Test F] 107 The PRNT is a serological test which utilizes the ability of a specific antibody to neutralize a 108 virus, in turn, preventing the virus from causing the formation of plaques in a cell monolayer. 109 In this study, Vero E6 cells were grown to a confluent monolayer in a 6 well plate. The 110 positive control was (Pooled Serum sample of Vaccinated and/or Covid-19 positive patient) 111 and viral stock diluted in Dulbecco's modification of Eagle medium (DMEM) was used as 112 negative control. 113 Interpretation is based on 50% neutralization, which is the last dilution of serum capable of 114 inhibiting 50% of the total plaques (virions). Negative control should have plaque count \geq 115 50%, positive control should be plaque count \leq 50% of negative control, and titer at which 116 50% reduction of plaques is there in comparison to the negative control is taken as the 117 antibody titer. For positive PRNT results, the cut off for positive is 1:20 dilution. 118 The study was done on 125 samples, of which 69 stored de-identified excess serum samples

119

collected from post-vaccination patients who requested post-vaccination antibody testing for

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

antibody levels against SARS-CoV -2 Virus and 56 negative serum samples from nonvaccinated COVID-19 negative patients. Each individual sample was tested using the PRNT method and with all the six different serological assays, and the results of each method were compared to the gold standard reference method which is PRNT. All serological assays were done based on manufacturers' guidelines and recommendations. Table 1 shows the details of the various serological assays evaluated in this study. Test A and F were enzyme linked immunosorbent assay (ELISA) based tests, tests B,D and E were chemiluminescent immunoassay (CLIA) based tests and test D was based on chemiluminescent microparticle immunoassay (CMIA) **Results** 125 samples were used in this study and PRNT was done on all 125 samples. Due to a lack of sufficient sample volume, some of the serological assays were not performed for certain samples. The borderline/equivocal results that were above the cut-off values for positive reports were considered positive. Table 2 shows the number of samples tested using each assay and the results of each. Test E had the highest sensitivity followed by test C and F. Test A had the highest specificity followed by test B and D. Test E though had the highest sensitivity had the lowest specificity compared to the other rapid tests as shown in Table 3. When the high sensitivity tests E and C were followed by serial testing with tests A and B with high specificity, it improved specificity of the tests E and C with a lower sensitivity. [Figure 1] and [Figure 2] Also employing two tests with high specificity in parallel for example test A with test B or test D, improved the sensitivity to 92% and 95% respectively, with only a slight loss in specificity. [Table 4] G42-Public

When a functional test like test A is combined with a quantitative test in parallel and serial testing, it shows that test A in parallel testing with test B or test D has the optimum sensitivity and specificity. (Table 4 and Table 5) Test A in serial testing with test B shows the maximum specificity. (Table 5) ROC curve was plotted for all the serological assays and the area under the curve was largest for test D followed by test A and test B, showing the best performance to differentiate positive and negative results compared to the PRNT results. (Figure 3 and Table 6) Based on the ROC optimum cutoffs for the tests were estimated and these were similar to the manufacturer's values for tests B and F. However, tests A, C, D and E showed different cut offs based on our ROC curves than the one recommended by the manufacturers. From the adapted ROC cut offs sensitivity, specificity, and overall agreement with the PRNT results were calculated. [Table 7] For test A, the manufacturers had an initial cut-off of 20% inhibition, which was changed due to the FDA recommendations to 30% to increase specificity. However, comparing test A results with the PRNT reports, showed 20% as optimum cut-off. The scatter plot of the distribution of % inhibition of test A based on the PRNT reports show the number of positive cases missed, with the increase in cut-off values by 10%. [Figure 4] Test A showed higher sensitivity and overall agreement with PRNT when 20% inhibition was used as a cut-off then the recommended 30%. [Figure 5] Discussion This study compared six immunoassays for detection of IgG antibodies against SARS-CoV-2 against the standard viral neutralization test PRNT.

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

In this study, tests A and B had the lowest sensitivity but had a high specificity and PPV. But studies that evaluated test A had demonstrated test A to have high sensitivity [6,7]. However, this might be because all these studies used cutoff as 20% inhibition, which was later changed according to FDA recommendation to 30%. [8] A study that compared test A to PRNT similar to our study used 30% as cutoff and showed that sensitivity ranged from 77% - 100% and specificity was 95% - 100% [9], which was similar to our study results when 30% cutoff was used. The ROC curve adapted cutoff for test A was around 20% inhibition and when 20% was used as a cutoff for test A the sensitivity increased to 92.31% and the overall agreement with the PRNT results was better (90.4%) suggesting 20% inhibition as a more optimum cut off for the test. Another study that evaluated test A suggested that the test might require specific cutoffs with respect to ethnic, geographical background and the prevalence of COVID-19 infections. The study also showed that introduction of an equivocal range with repeat testing within the range of 18 – 22% can reduce the false positive results.[10] Based on the ROC threshold values, tests D and E did not correlate with the manufacturers cut-off. Raising the cut-offs for tests D and E as per the ROC values showed increased specificity and agreement with the PRNT results without much change in sensitivity. However, for test C raising the cut-off increased specificity with a huge drop in sensitivity, but the agreement with the PRNT results were better. Studies suggest revision of cut- off values provided by manufacturers, as most of the assay validation are done on a small sample size and among specific ethnic or regional group.[11] Therefore more evaluation studies and optimum cut-offs need to be defined before these serological assays are used in large scale to evaluate vaccination status of the population.

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

Test E had the highest sensitivity in this study as reported in similar studies, but these studies have also reported high specificity, which our study did not find. [12,13] The sensitivity of test B was similar to that reported in other studies [12]. Studies evaluating C and E demonstrated higher specificity of test C and test E compared to our study. [14] A meta-analysis on antibody tests for SARS-CoV-2 showed that tests using ELISA and CLIAbased methods performed better [5]. In our study test A and F are based on ELISA and tests B, D and E were CLIA-based tests. While tests D, E and F showed higher sensitivities, the sensitivities of test A and B were low. Test C was evaluated by a study which compared antibodies in post-vaccination patients compared with pre-pandemic serum samples and claims high sensitivity and a specificity of 100%. While our study showed that the sensitivity of test C was high, the specificity was low compared to this study. [15] This might be because these studies have not compared the assays with the PRNT method, but with the RT-PCR assay validation. Test D had good sensitivity and specificity with the highest agreement with the PRNT results, as also supported by another that evaluated test D. [16] In addition, when a functional test like test A was tested with quantitative tests in parallel, it is observed that the overall sensitivity increases. An optimum sensitivity and specificity are achieved when test A is done in parallel with test B. This kind of combination of two antibody tests are being studied and it shows that it increases the ability to capture the positive results. [17] The CDC recommends serological tests with high sensitivity and specificity and tests detecting IgG or both IgG and IgM. This is because currently serological tests are recommended by CDC only for identifying persons with previous infections or to identify resolving infections and for better understanding the epidemiology of SARS-CoV-2. [18]

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

However, these antibody tests help us understand the development of immune response and the longevity of the antibodies developed post-vaccination for COVID-19. This surveillance becomes essential to identify vaccine efficiency and make recommendation on booster doses and the intervals for vaccination. The WHO, in collaboration with Coalition for Epidemic Preparedness Innovations (CEPI), and the National Institute for Biological Standards and Control (NIBSC), has come up with the International standards for anti-SARS-CoV-2 immunoglobulins. This is very crucial for a standard comparison as vaccine developers have been using various immunoassays with different measuring units making the comparison of immunogenicity difficult. Hence with these recommendations future studies can make the comparison of immunogenicity more standardized and will be less challenging. [19] Most COVID-19 vaccinations use the S protein or S-domains as immunogen target. [20] Therefore these serological assays that target antibodies against S protein and the RBD directed IgG detection serve as a good candidate for evaluating vaccine response. Therefore, keeping this in mind, when serological assays are being used to assess post-vaccine immune status, a balance of all parameters needs to be considered rather than emphasizing more on only high specificity. This is particularly relevant in the current situation where vaccination is happening around the globe and the percentage of vaccination is increasing, high sensitivity assays will result in reporting a lower percentage of false negative reports. This will help assess the immune status and avoids panic about lack of vaccine response. Thus, recommendations based on a balance of all these parameters are needed. **Strengths** Most evaluation studies compare the serological assays with RT-PCR reports. This study is one of its kind that compares commercial serological assays using the same serum sample

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

G42-Public

and by evaluating the results with the gold standard PRNT reports. Thus, this study reduces the biases and provides a standard comparison. Limitations The number of samples were limited and additional parameters like days post vaccination and the type of vaccine were not taken into consideration in this study, which could have provided further insights on the serological assay performances. Conclusion Serological assays that are commercially available are very promising and show good agreement with the standard PRNT results. We recommend further studies of these serological assays with large number of samples, to understand more about the performance of these assays. Moreover, performing two tests in parallel testing improves the sensitivity and a better alternative to conventional PRNT, however cost-effective evaluations are needed to recommend these. We suggest optimization of the cut offs values for these serological assays considering the prevalence, ethnic and geographical variations. Recommendations based on the balance of all performance indicators rather than just specificity will help in the application of these serological assays in assessing post-vaccination status. **Funding statement** The study was not funded by any funding body, it was done in Biogenix lab as a part of research. Ethics approval and consent to participate. The Ethics approval was obtained from Department of Health (DOH) Institutional review board (IRB), Abu Dhabi. All methods were carried out in accordance with relevant guidelines and regulations.

Informed consent statement

- 263 Informed consent was waived off by the Department of Health (DOH) Institutional review
- board (IRB), Abu Dhabi.

Data Availability

- The data is available with the corresponding author, Dr. Sally, Director of Biogenix G42 lab
- and will be produced on request.

268 Conflict of interest

- 269 The authors declare that they have no conflict of interest regarding the publication of this
- 270 paper.

262

265

271 References

- 1. Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Y, Hayford K,
- Luquero FJ, Mina MJ, Rodriguez-Barraquer I, Wu JT. Serology for SARS-CoV-2:
- apprehensions, opportunities, and the path forward. Science Immunology. 2020 May
- 275 19;5(47).
- 2. Amanat F, Stadlbauer D, Strohmeier S, Nguyen TH, Chromikova V, McMahon M, et
- al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nature
- 278 medicine. 2020 Jul;26(7):1033-6.
- 3. Perera, R.A., Mok, C.K., Tsang, O.T., Lv, H., Ko, R.L., Wu, N.C., Yuan, M., Leung,
- 280 W.S., Chan, J.M., Chik, T.S. and Choi, C.Y., 2020. Serological assays for severe
- acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March
- 282 2020. Eurosurveillance, 25(16), p.2000421.

- 4. Okba NM, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al.
- Severe acute respiratory syndrome coronavirus 2-specific antibody responses in
- coronavirus disease 2019 patients. Emerg. Infect. Diseases. 2020;26(7).
- 5. Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody Tests in
- Detecting SARS-CoV-2 Infection: A Meta-Analysis. *Diagnostics*. 2020; 10(5):319.
- 6. Putcharoen O, Wacharapluesadee S, Chia WN, Paitoonpong L, Tan CW,
- Suwanpimolkul G, et al. Early detection of neutralizing antibodies against SARS-
- 290 CoV-2 in COVID-19 patients in Thailand. PloS one. 2021 Feb 12;16(2):e0246864
- 7. Müller K, Girl P, von Buttlar H, Dobler G, Wölfel R. Comparison of two commercial
- surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2. Journal
- of Virological Methods. 2021 Mar 8:114122
- 8. Food and Drug Administration (FDA). USA. cPass™ SARS-CoV-2 Neutralization
- Antibody Detection Kit. Available at: https://www.fda.gov/media/143583/download.
- 296 (Accessed on 3/3/2021)
- 9. Papenburg J, Cheng MP, Corsini R, Caya C, Mendoza EJ, Manguiat KJ, et al.
- 298 Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for
- Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an
- Anti-RBD ELISA Assay. medRxiv. 2021 Jan 1.
- 301 10. Bond K, Nicholson S, Lim SM, Karapanagiotidis T, Williams E, Johnson D, Hoang
- T, Sia C, Purcell D, Mordant F, Lewin SR. Evaluation of serological tests for SARS-
- 303 CoV-2: Implications for serology testing in a low-prevalence setting. The Journal of
- infectious diseases. 2020 Oct 15;222(8):1280-8.
- 305 11. Marzia N, Massimo P, Sandro G, Ciotti M, Miano R, Massimo A, Bernardini S.
- SARS-CoV-2 infection serology: a useful tool to overcome lockdown?. Cell Death
- 307 Discovery. 2020;6(1).

12. Manthei DM, Whalen JF, Schroeder LF, Sinay AM, Li SH, Valdez R, Giacherio DA, Gherasim C. Differences in performance characteristics among four high-throughput assays for the detection of antibodies against SARS-CoV-2 using a common set of patient samples. American journal of clinical pathology. 2021 Feb;155(2):267-79. 13. Wakita M, Idei M, Saito K, Horiuchi Y, Yamatani K, Ishikawa S, Yamamoto T, Igawa G, Hinata M, Kadota K, Kurosawa T. Comparison of the clinical performance and usefulness of five SARS-CoV-2 antibody tests. Plos one. 2021 Feb 8;16(2):e0246536. 14. Ainsworth M, Andersson M, Auckland K, Baillie JK, Barnes E, Beer S, Beveridge A, Bibi S, Blackwell L, Borak M, Bown A. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. The Lancet Infectious Diseases. 2020 Dec 1;20(12):1390-400. 15. Narasimhan M, Mahimainathan L, Raj E, Clark AE, Markantonis J, Green A, et al. Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays in infected, recovered, and vaccinated groups. medRxiv. 2021 Jan 1. 16. Bonelli F, Blocki FA, Bunnell T, Chu E, De La O A, Grenache DG, et al. Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies. Clin Chem Lab Med. 2021 Mar 12. doi: 10.1515/cclm-2021-0023. Epub ahead of print. PMID: 33711225. 17. Schnurra C, Reiners N, Biemann R, Kaiser T, Trawinski H, Jassoy C. Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests. J Clin Virol. 2020 Aug;129:104544. doi: 10.1016/j.jcv.2020.104544. Epub 2020 Jul 6. PMID: 32663788; PMCID: PMC7836838.

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

- 18. Center for Disease Control and Prevention (CDC). COVID-19. Interim guidelines for COVID-19 antibody testing. Available at: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html (Accessed on 3/3/2021)
- 19. Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, Plotkin S, Knezevic I. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. The Lancet. 2021 Mar 23.
 - 20. Lee N, McGeer A. The starting line for COVID-19 vaccine development. The Lancet. 2020 Jun 13;395(10240):1815-6.

Table 1: Details of the six commercial serological assays

Test	Reagent/kit	Method	Manufacturer	Isotype	Target	Run time
					protein	(minutes)
A	cPass SARS-COV-2	ELISA	Genscript	IgG	RBD	180
	surrogate virus				unit of	
	neutralization test kit				S1	
В	Diasorin SARS-CoV-2	CLIA	Diasorin	IgG	S1/S2	35
	S1/S2 IgG detection					
С	Alinity SARS-CoV-2 IgG	CMIA	Abbott	IgG	RBD	20
	II				unit of	
					S1	
D	SARS-CoV-2 TrimericS	CLIA	Diasorin	IgG	RBD	20
	IgG				unit of	
					S1	
Е	Elecsys Anti-SARS-CoV-2	CLIA	Roche	IgG &	RBD	20
	– cobas			IgM	unit of	
					S1	
F	AESKULISA (AESKU	ELISA	AESKU	IgG	S1	180
	Enzyme Linked					
	Immunosorbent Assay)					

Table 2: Results of all six commercial serological assays.

Assay	Positive	Negative	Total
Test A	52	73	125
Test B	43	61	104
Test C	67	37	104
Test D	50	53	103
Test E	76	20	96
Test F	61	38	99

Table 3: Performance indicators of the serological assays compared to PRNT

Assay	Sensitivity	Specificity	PPV	NPV	Overall
	(95% CI)	(95% CI)	(95% CI)	(95% CI)	agreement
					with PRNT
					results (95% CI)
Test	71.07	94.64	94.23	72.60	81.6

A	(58.8–81.3)	(85.1-98.8)	(84.1-98.8)	(60.9-82.4)	(73.7-87.9)
Test	75.47	94.12	93.02	78.69	84.61
В	(61.7-86.2)	(83.8-98.8)	(80.9-98.5)	(66.3-88.1)	(76.2-90.9)
Test	98.11	70.59	77.61	97.30	84.62
С	(89.9-99.9)	(56.1-82.5)	(65.8-86.9)	(85.8-99.9)	(76.22-90.94)
Test	84.91	90	90	84.91	87.37
D	(72.4-93.2)	(78.1-96.6)	(78.1-96.6)	(72.4-93.2)	(79.4-93.1)
Test	100	41.67	63.16	100	70.83
Е	(92.6-100)	(27.6-56.7)	(51.3-73.9)	(83.1-100)	(60.7-79.7)
Test	92.31	72.34	78.69	89.47	82.82
F	(81.5-97.9)	(57.4-84.4)	(66.3-88.1)	(75.2-97.1)	(73.9-89.7)

Table 4: Test A in parallel testing with other serological tests

Parallel testing		Sensitivity	Specificity
Test A	Test B	92.86	89.07
	Test C	99.46	66.80
	Test D	95.63	85.17
	Test E	100	39.72
	Test F	97.77	68.46

Table 5: Test A in serial testing with other serological tests

Serial testing		Sensitivity	Specificity
Test A	Test B	53.53	99.69

351

Test C	69.65	98.41
Test D	60.27	99.46
Test E	71.0	96.9
Test F	65.54	98.52

Table 6: Area under the curve (AUC) for the serological assays

Antibody tests	AUC	95% Confidence Interval
Test A	0.939	(0.888 - 0.990)
Test B	0.935	(0.885 - 0.986)
Test C	0.860	(0.784 -0.936)
Test D	0.953	(0.912 - 0.994)
Test E	0.839	(0.751 - 0.927)
Test F	0.928	(0.871 - 0.984)

Table 7: Optimum cut-offs based on the ROC curves and their performances.

	Cut offs	Sensitivity	Specificity	Overall agreement
				with PRNT results
Test A	Manufacturer's cut off – 30%	71.0	94.23	81.6
	Based on ROC cut off – 20%	92.31	87.5	90.4
Test C	Manufacturer's cut off - 50	98.11	70.59	84.62

	Based on ROC cut off - 150	83.01	88.23	85.57
Test D	Manufacturer's cut off - 33.8	84.91	90	87.37
	Based on ROC cut off - 40	84.90	96.0	90.29
Test E	Manufacturer's cut off - 0.8	100	41.67	70.83
	Based on ROC cut off - 5	93.75	70.83	82.29

^{*} Tests B and F showed ROC based cut offs similar to the manufacturer's values.

Figure 1: Serial testing of test C with test A and test B



Figure 2: Serial testing of test E with test A and test B

362

363

364

365

367




Figure 3: ROC curves for the serological assays




Figure 4: Scatter plot of test A % inhibition based on results of the PRNT




Figure 5: Comparison of the test A performance based on two different cut-off values

